Objectives: Immune checkpoint therapy has been promising in renal cell carcinoma, but no validated clinically relevant biomarkers exist. Metastatic deposits may have discordant biomarker expression. Methods: Fifty matched pairs of primary and metastatic kidney tumors were evaluated via immunohistochemistry for immune checkpoint proteins PD-1, PD-L1, and PD-L2 and the T-cell and macrophage surface markers CD3, FOXP3, and CD163. Semiquantitative scores incorporating prevalence of both tumor and nontumor labeling were compared between metastatic and primary kidney tumor specimens. Results: A large minority of patients had discordant expression of PD-1 (31.2%), PD-L1 (22.5%), or PD-L2 (21.5%) between primary and metastatic sites. The expression of the novel marker PD-L2 correlated with both PD-1 (r = 0.47, P = .02) and PD-L1 (r = 0.67, P < .001) in metastatic deposits. Conclusions: This study demonstrates that renal clear cell carcinoma primary tumors and metastatic deposits have some discordance in the expression of PD-L1, PD-1, and PD-L2.
Objectives: Immune checkpoint therapy has been promising in renal cell carcinoma, but no validated clinically relevant biomarkers exist. Metastatic deposits may have discordant biomarker expression. Methods: Fifty matched pairs of primary and metastatic kidney tumors were evaluated via immunohistochemistry for immune checkpoint proteins PD-1, PD-L1, and PD-L2 and the T-cell and macrophage surface markers CD3, FOXP3, and CD163. Semiquantitative scores incorporating prevalence of both tumor and nontumor labeling were compared between metastatic and primary kidney tumor specimens. Results: A large minority of patients had discordant expression of PD-1 (31.2%), PD-L1 (22.5%), or PD-L2 (21.5%) between primary and metastatic sites. The expression of the novel marker PD-L2 correlated with both PD-1 (r = 0.47, P = .02) and PD-L1 (r = 0.67, P < .001) in metastatic deposits. Conclusions: This study demonstrates that renal clear cell carcinoma primary tumors and metastatic deposits have some discordance in the expression of PD-L1, PD-1, and PD-L2.
Authors: Michael S Khodadoust; Alain H Rook; Pierluigi Porcu; Francine Foss; Alison J Moskowitz; Andrei Shustov; Satish Shanbhag; Lubomir Sokol; Steven P Fling; Nirasha Ramchurren; Robert Pierce; Asa Davis; Richard Shine; Shufeng Li; Sophia Fong; Jinah Kim; Yi Yang; Wendy M Blumenschein; Jennifer H Yearley; Biswajit Das; Rajesh Patidar; Vivekananda Datta; Erin Cantu; Justine N McCutcheon; Chris Karlovich; P Mickey Williams; Priyanka B Subrahmanyam; Holden T Maecker; Steven M Horwitz; Elad Sharon; Holbrook E Kohrt; Martin A Cheever; Youn H Kim Journal: J Clin Oncol Date: 2019-09-18 Impact factor: 44.544
Authors: Gorka Larrinaga; Jon Danel Solano-Iturri; Peio Errarte; Miguel Unda; Ana Loizaga-Iriarte; Amparo Pérez-Fernández; Enrique Echevarría; Aintzane Asumendi; Claudia Manini; Javier C Angulo; José I López Journal: Cancers (Basel) Date: 2021-02-07 Impact factor: 6.639
Authors: Sjoerd P F T Nota; Ahmad Al-Sukaini; Shalin S Patel; Francesco Sabbatino; G Petur Nielsen; Vikram Deshpande; Jennifer H Yearley; Soldano Ferrone; Xinhui Wang; Joseph H Schwab Journal: Front Oncol Date: 2021-04-12 Impact factor: 5.738
Authors: Darci Phillips; Magdalena Matusiak; Belén Rivero Gutierrez; Salil S Bhate; Graham L Barlow; Sizun Jiang; Janos Demeter; Kimberly S Smythe; Robert H Pierce; Steven P Fling; Nirasha Ramchurren; Martin A Cheever; Yury Goltsev; Robert B West; Michael S Khodadoust; Youn H Kim; Christian M Schürch; Garry P Nolan Journal: Nat Commun Date: 2021-11-18 Impact factor: 14.919
Authors: Katharina Möller; Christoph Fraune; Niclas C Blessin; Maximilian Lennartz; Martina Kluth; Claudia Hube-Magg; Linnea Lindhorst; Roland Dahlem; Margit Fisch; Till Eichenauer; Silke Riechardt; Ronald Simon; Guido Sauter; Franziska Büscheck; Wolfgang Höppner; Cord Matthies; Ousman Doh; Till Krech; Andreas H Marx; Henrik Zecha; Michael Rink; Stefan Steurer; Till S Clauditz Journal: Int Urol Nephrol Date: 2021-04-01 Impact factor: 2.370